医学
伊马替尼
甲磺酸伊马替尼
酪氨酸激酶抑制剂
耐受性
内科学
胃肠病学
舒尼替尼
髓系白血病
临床试验
酪氨酸激酶
肿瘤科
不利影响
药理学
癌症
受体
作者
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton Eisenberg,Peter Roberts,Michael C. Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Saša Dimitrijević,Brian J. Druker,Christopher L. Corless,Christopher D.�M. Fletcher
摘要
Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
Rondab
FIN
cc
有人
YifanWang
herococa
笨笨棒球
Sandy
乐乐乐乐乐乐
MchemG
无情的君浩
GingerF
柯一一
ceeray23
拉长的傲旋
yyds
PPP
andrele
鸣笛
cherlie
皖公网安备34019202002308
